Business Overview

Cardinal Health is one of the largest healthcare distributors in the United States, sitting in the middle of the supply chain that connects drug manufacturers, medical-device makers, and the pharmacies, hospitals, and clinics that ultimately treat patients. The vast majority of its revenue comes from its Pharmaceutical and Specialty Solutions segment, where the company buys branded, generic, and specialty drugs in bulk from manufacturers and resells and delivers them to retail pharmacy chains, independent pharmacies, hospital systems, and physician practices. Because this is a distribution business, headline revenue is enormous but margins are razor-thin: Cardinal earns its money on the spread between what it pays and what it charges, on volume, and increasingly on services layered on top of moving product.

Its second pillar is the Medical segment (sometimes grouped with newer growth platforms the company has emphasized, such as at-home solutions and specialty services), which manufactures and distributes medical and surgical products, including Cardinal Health-branded consumables like gloves, gowns, surgical kits, and other supplies sold to hospitals and labs. A meaningful share of segment profit in the Pharmaceutical business comes from generic drug sourcing and from manufacturer fees and rebates rather than the simple buy-sell margin. Cardinal also generates economics from its specialty distribution and services arm, which handles complex, high-cost therapies in areas like oncology, and from solutions aimed at managing care in the home. In short, Cardinal Health makes money primarily by being an efficient, high-volume logistics and sourcing engine for medicines and medical supplies, supplemented by higher-value services around specialty drugs and the medical product portfolio.

Financial Trends

Cardinal Health's financial profile is the classic distributor shape: very large top-line revenue paired with extremely low operating and net margins measured in low single-digit percentages or less. Investors should not read its revenue scale as a sign of profitability; the more telling figures are segment profit, gross margin trends, and operating cash flow. Pharmaceutical revenue is heavily influenced by a handful of very large customers and by branded drug price inflation, so revenue can swing on customer mix and pricing dynamics even when underlying volume is stable.

• Growth drivers: rising prescription volumes, an aging population, the shift toward high-cost specialty and biologic therapies, growth in generics (which often carry better economics than branded distribution), and expansion of services around oncology and home-based care.
• Margin structure: the Pharmaceutical segment is high-volume/low-margin, with profit leverage tied to generic sourcing economics and manufacturer programs; the Medical segment has historically been a smaller profit contributor and has been a focus of turnaround and cost actions.
• Cash and capital: the model is working-capital intensive, so inventory levels, receivables, and payables (and the timing differences among them) drive swings in free cash flow. Cardinal has historically returned cash through dividends and share repurchases and has carried debt, making net leverage and interest coverage relevant.
• One-time noise: reported GAAP results are frequently affected by litigation charges, goodwill or intangible impairments, and segment restructuring, so adjusted (non-GAAP) operating earnings and segment profit are where management directs attention.

What to Watch in the Filings

Because Cardinal Health's reported revenue is huge and its margins are thin, the most useful disclosures sit below the top line. When reading its 10-K and 10-Q, focus on:

• Segment profit, not just revenue: the breakdown between Pharmaceutical/Specialty Solutions and Medical (and any newer reporting groupings) shows where money is actually earned and which segment is dragging or improving.
• Customer concentration: the filings disclose how much revenue comes from the largest pharmacy customers. A renewal, loss, or renegotiation of a major contract is highly material and often surfaces in 8-Ks and MD&A.
• Generics program and brand price inflation commentary: management discussion of generic sourcing economics, pricing trends, and manufacturer fees explains margin movement more than headline sales do.
• Litigation and the opioid settlement: review the legal-proceedings notes and contingencies for the status, remaining payments, and cash-flow timing of the multi-year opioid distribution settlement and any other litigation.
• Cash flow and working capital: watch operating cash flow versus net income, plus inventory and payables swings; distributor free cash flow can be lumpy quarter to quarter.
• Guidance and adjusted EPS bridges: 8-K earnings releases lay out non-GAAP adjustments (impairments, litigation, restructuring) and full-year guidance, which the market reacts to closely.
• Capital returns and leverage: dividend declarations, buyback activity, and debt maturities in the financing sections and subsequent-events notes.

Key Risks

• Ultra-thin margins: as a distributor, small changes in pricing, sourcing costs, or customer mix can have an outsized effect on profit, leaving little cushion for error.
• Customer concentration: a large portion of Pharmaceutical revenue is tied to a small number of major pharmacy and retail customers; losing or repricing one of these relationships would materially affect results.
• Opioid and other litigation: Cardinal is a party to the broad opioid distribution settlement and faces ongoing legal and regulatory exposure, with multi-year cash payment obligations and reputational risk.
• Drug pricing and policy: changes in branded drug price inflation, generic pricing pressure, drug-pricing reform, reimbursement changes, and 340B program dynamics can compress economics.
• Supplier and manufacturer dependence: profitability relies partly on manufacturer fees, rebates, and generic sourcing arrangements that can change.
• Medical segment execution: the Medical business has faced cost inflation, sourcing, and turnaround challenges, and is sensitive to commodity and freight costs and supply-chain disruption.
• Regulatory and DEA oversight: as a controlled-substance distributor, Cardinal operates under strict DEA and FDA regulation, where compliance failures carry fines, suspensions, and reputational harm.
• Leverage and capital allocation: debt levels and interest costs, alongside commitments to dividends and buybacks, constrain flexibility if cash flow weakens.

Frequently Asked Questions